Healthpeak cited other-than-temporary impairment charges on two lab unconsolidated joint ventures, a decrease in gain on sales of real estate related to fewer real estate dispositions, and an increase in interest expense as factors in the decrease in net income applicable to common shares for Q3 2025.

10-QQuarterly reportFiled Oct 24, 2025Period of report Sep 30, 2025Summary published (UTC) Oct 10, 2026

Key points

AI summary

Healthpeak cited other-than-temporary impairment charges on two lab unconsolidated joint ventures, a decrease in gain on sales of real estate related to fewer real estate dispositions, and an increase in interest expense as factors in the decrease in net income applicable to common shares for Q3 2025.
The company cited the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, and the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, as factors in the increase in interest expense.
Healthpeak said material cash requirements related to debt as of September 30, 2025 increased by $416 million compared to December 31, 2024, totaling $9.1 billion, with the repayment of $452 million aggregate principal amount of 4.00% notes and $348 million aggregate principal amount of 3.40% notes providing partial offset.
The company said net cash provided by operating activities for the 9 months ended September 30, 2025 increased by $171 million compared to the prior-year period, citing a decrease in merger-related costs and an increase in Adjusted NOI from real estate acquired as part of the Merger as factors.

Key figures

Quarter ended September 30, 2025

Revenue: $706M
Net income: −$117M
EPS: −$0.17

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Factors in the Decrease in Net Income Applicable to Common Shares for Q3

Healthpeak cited other-than-temporary impairment charges on two lab unconsolidated joint ventures, a decrease in gain on sales of real estate related to fewer real estate dispositions, and an increase in interest expense as factors in the decrease in net income applicable to common shares for Q3 2025.

Source · Based on the MD&A text of the filing

Issuance of New Senior Unsecured Notes

The company cited the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, and the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, as factors in the increase in interest expense.

Source · Based on the MD&A text of the filing

Changes in Material Cash Requirements Related to Debt

Healthpeak said material cash requirements related to debt as of September 30, 2025 increased by $416 million compared to December 31, 2024, totaling $9.1 billion, with the repayment of $452 million aggregate principal amount of 4.00% notes and $348 million aggregate principal amount of 3.40% notes providing partial offset.

Source · Based on the MD&A text of the filing

Increase in Net Cash Provided by Operating Activities for the 9 Months

The company said net cash provided by operating activities for the 9 months ended September 30, 2025 increased by $171 million compared to the prior-year period, citing a decrease in merger-related costs and an increase in Adjusted NOI from real estate acquired as part of the Merger as factors.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.